Bone metastases are a hallmark of advanced prostate cancer and may drive the morbidity and mortality of the disease in patients with a poor prognosis. The pathogenesis of bone metastasis involves the interaction between cancer cells, normal bone cells and the bone microenvironment.
INTRODUCTION
Metastasis to the bone is a hallmark of advanced prostate cancer, and skeletal complications are a main cause of morbidity in patients with metastatic prostate cancer. 1 Bone is the dominant site of metastasis from advanced prostate cancer, which, in contrast to other common solid tumors, forms primarily osteoblastic lesions. 2 Patients with metastatic prostate cancer and bone metastasis can experience complications known as skeletal-related events (SREs), which include bone pain, fractures and spinal cord compression, 3 resulting in negative impacts on quality of life and functional independence. 2 Several treatment options for metastatic castration-resistant prostate cancer (mCRPC), including abiraterone, enzalutamide and radium-223, have shown survival benefits as well as improvements in bone-related endpoints in phase III clinical trials. [4] [5] [6] [7] In addition, zoledronic acid, a bisphosphonate, and denosumab, an inhibitor of the receptor activator of reviews the mechanisms of bone metastasis and clinical data for these anti-resorptive bone-targeted agents.
MECHANISMS OF BONE METASTASIS IN PROSTATE CANCER
Bone metastasis involves the complex interaction between cancer cells, normal bone cells and the bone microenvironment, leading to a severe disruption in physiological bone remodeling. 8 In the metastatic colonization of the bone, prostate tumor cells induce an abnormal increase in osteoblast-mediated bone resorption through the release of several growth factors and cytokines. 8 These factors trigger the activation of the RANK/RANK ligand pathway. 8 Generated by osteoblasts, RANK ligand binds to its receptor RANK on the surface of osteoclasts, thereby facilitating their activities. 8, 9 Boosted osteolysis is associated with the release of growth factors and cytokines from the bone matrix, enabling the progression of prostate tumor cells. 8 
BONE-MODIFYING AGENTS: ZOLEDRONIC ACID AND DENOSUMAB
Two antiresorptive bone-targeted therapies, zoledronic acid and denosumab, have been demonstrated to reduce SREs in mCRPC patients with bone metastases.
Zoledronic acid, a bisphosphonate, is able to prevent bone resorption via reduced osteoclast differentiation and enhanced osteoblast survival, 13 lowering the risk of SREs in patients with bone metastasis.
As shown in a phase III study that randomized mCRPC patients with bone metastases to zoledronic acid 4 mg, 8 mg (subsequently adjusted to 4 mg; 8/4) or placebo, those who received the agent experienced proportionally fewer SREs (4 mg: 33.2%, P = 0.021; 8/4 mg: 38.5%, P = 0.222; placebo: 44.2%) and had a longer median time to first SRE (4 mg: not reached, P = 0.011; 8/4 mg: 363 days, P = 0.491; placebo: 321 days) compared with the placebo group. 14 Denosumab, a human monoclonal antibody against the RANK ligand, has been found to be feasible for treating bone metastases in mCRPC patients and more effective than zoledronic acid for delaying SREs. 15, 16 In a randomized, double-blind trial, denosumab significantly delayed the median time to first on-study SRE compared with zoledronic acid (20.7 months vs 17.1 months; hazard ratio = 0.82; 95% confidence interval [CI], 0.71-0.95; P = 0.008 [superiority]). 16 In addition, there were significantly fewer SREs with denosumab than with zoledronic acid, with a difference of 90 events between the two treatment groups, and denosumab was associated with an 18% risk reduction for first and subsequent on-study SREs over zoledronic acid (rate ratio = 0.82; 95% CI, 0.71-0.94; P = 0.008 [superiority]). 16 In support of the SRE results, denosumab was associated with significantly greater reductions in the levels of urinary N-telopeptide (P < 0.0001) and serum bone-specific alkaline phosphatase (P < 0.0001) compared with zoledronic acid. 16 There was no significant difference in the rates of all or serious adverse events between the two treatment groups, with infrequent reports of osteonecrosis of the jaw (denosumab: 2%; zoledronic acid: 1%, P = 0.09), and more hypocalcemia (mostly asymptomatic) events observed in the denosumab group (13% vs 6% for zoledronic acid, P < 0.0001). 16 Although zoledronic acid had been shown to delay the median time to first SRE by approximately 6 months compared with placebo (P = 0.009), 17 more recent evidence has revealed that denosumab provides additional benefit over zoledronic acid for delaying SREs in men with bone metastasis from mCRPC. 16 
CONCOMITANT USE OF EMERGING mCRPC THERAPIES AND BONE-TARGETED AGENTS
In real-world clinical practice, denosumab and zoledronic acid have been widely prescribed concomitantly with emerging mCRPC therapies. According to a cross-sectional survey conducted in several European countries, among men with bone metastases from prostate cancer who were treated with abiraterone, enzalutamide or radium-223, 73% were also receiving a bone-targeted agent, predominately denosumab or zoledronic acid. 18 The main reasons given by physicians for initiating a bone-targeted agent within 3 months of a bone metastases diagnosis were bone pain (72%), high risk of bone complications (66%) and location of bone metastases (54%). 18 In contrast, the main reasons for not administering a bone-targeted agent were perceived low risk of bone complications (59%), focus on treating the primary tumor (50%) and very recent diagnosis (27%). 18 Based on the real-world findings, bone-targeted agents are the backbone of supportive care for prostate cancer patients with bone metastases who are treated with novel anticancer therapies.
GUIDELINES FOR THE USE OF BONE-TARGETED AGENTS IN THE MANAGEMENT OF PROSTATE CANCER
Recent international guidelines have recommended denosumab or zoledronic acid as a preventive treatment for SREs in mCRPC patients with bone metastases. [19] [20] [21] The recommendation was also proposed in a consensus on the management of metastatic prostate cancer established by a Hong Kong expert panel, 22 which noted the negative impact of SREs on overall and cancer-specific survival in a local study of prostate cancer patients with bone metastases. 23 
CONCLUSION
SREs can impact quality of life and survival outcomes of patients with prostate cancer and bone metastases. Current evidence shows that denosumab has a superior effect on delaying SREs compared with zoledronic acid in men with mCRPC and bone metastases. Although the optimal sequencing of prescription remains undetermined, bonemodifying agents can be adopted concomitantly with anticancer therapies among mCRPC patients with bone metastases to reduce the risk of SREs.
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